Alpine Woods Capital Investors’s Tvardi Therapeutics TVRD Stock Holding History

Alpine Woods Capital Investors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,762	Closed	-$1.6M	–	204
2022 Q3	$1.6M	Sell	4,762 -33	-0.7%	-$12K	0.22%	111
2022 Q2	$1.58M	Sell	4,795 -11	-0.2%	-$3.86K	0.2%	119
2022 Q1	$2.1M	Buy	4,806 +1	+0%	+$410	0.22%	118
2021 Q4	$2.11M	Sell	4,805 -324	-6%	-$163K	0.21%	122
2021 Q3	$2.85M	Buy	5,129 +3,756	+274%	+$1.88M	0.31%	103
2021 Q2	$705K	Sell	1,373 -316	-19%	-$200K	0.07%	167
2021 Q1	$1.32M	Buy	1,689 +80	+5%	+$54.8K	0.15%	144
2020 Q4	$876K	Buy	1,609 +1,102	+217%	+$578K	0.11%	162
2020 Q3	$232K	Buy	+507	New	+$295K	0.04%	222

Other funds holding TVRD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alpine Woods Capital Investors's TVRD Position: Q4 2022 in Review

Alpine Woods Capital Investors sold out of Tvardi Therapeutics (TVRD) in Q4 2022, closing a stake of 4,762 shares — an estimated $1.6M sold.

Alpine Woods Capital Investors first reported a position in TVRD in Q3 2020 and held it in 9 quarters. The position peaked at $2.85M in Q3 2021. 160 funds tracked by Wall St. Rank hold TVRD as of Q4 2022.

Alpine Woods Capital Investors reported no remaining Tvardi Therapeutics position as of Q4 2022 after selling out during the quarter.
Alpine Woods Capital Investors sold 4,762 Tvardi Therapeutics shares in Q4 2022, an estimated $1.6M.
Alpine Woods Capital Investors first reported a position in Tvardi Therapeutics in Q3 2020 and held it in 9 quarters.
Alpine Woods Capital Investors's Tvardi Therapeutics position peaked at $2.85M in Q3 2021.
160 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2022.

Based on Alpine Woods Capital Investors's 13F filing for Q4 2022, filed 8 Feb 2023.